高级检索
当前位置: 首页 > 详情页

LINC01088 regulates the miR-95/LATS2 pathway through the ceRNA mechanism to inhibit the growth, invasion and migration of gastric cancer cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Qual Control Off, Hosp 4, Shijiazhuang, Hebei, Peoples R China [2]Hebei Med Univ, Dept Surg 3, Hosp 4, Shijiazhuang, Hebei, Peoples R China
出处:
ISSN:

关键词: gastric cancer LINC01088 invasion migration proliferation microRNA-95 large tumor suppressor kinase 2

摘要:
Background: In gastric cancer, a malignant condition with a dismal prognosis, long non-coding RNAs (LncRNAs) play a significant regulatory role. They often compete with microRNAs through the ceRNA mechanism to affect the expression of target mRNA. However, the specific clinical value and mechanism of action of LncRNA in gastric cancer are still unclear. Methods: This study detected the expression and clinical value of LINC01088 in gastric cancer tissues. Furthermore, the biological functions of LINC01088 and the regulation mechanism of the miR-95/LATS2 pathway were explored.Results: LINC01088 and LATS2 mRNA expression decreased, and miR-95 increased in gastric cancer tissues. LINC01088 has an excellent positive correlation with LATS2 mRNA, which may be a ceRNA pair; LINC01088 has binding sites with miR-95. Gene interference tests on gastric cancer cell lines revealed that LINC01088 could prevent gastric cancer cells from proliferating, invading, and migrating. The function of LINC01088 is achieved by regulating the miR-95/LATS2 pathway through the ceRNA mechanism.Conclusion: The results of this study show that LINC01088 expression is significantly reduced in gastric cancer tissues and cell lines. LINC01088 inhibits gastric cancer cells' proliferation, invasion, and migration by regulating the miR-95/LATS2 pathway via the ceRNA mechanism.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 病理学 4 区 药学 4 区 免疫学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 病理学 4 区 免疫学 4 区 药学
JCR分区:
出版当年[2022]版:
Q2 PATHOLOGY Q2 PHARMACOLOGY & PHARMACY Q3 IMMUNOLOGY
最新[2024]版:
Q2 PATHOLOGY Q3 IMMUNOLOGY Q3 PHARMACOLOGY & PHARMACY

影响因子: 最新[2024版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Qual Control Off, Hosp 4, Shijiazhuang, Hebei, Peoples R China
通讯作者:
通讯机构: [2]Hebei Med Univ, Dept Surg 3, Hosp 4, Shijiazhuang, Hebei, Peoples R China [*1]Hebei Med Univ, Dept Surg 3, Hosp 4, Canc Inst, Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号